Biogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Trial of Long-Acting Hemophilia B Therapy
26-Jan-2010 -
Biogen Idec and Swedish Orphan Biovitrum y announced that the first patient was dosed in a registrational, open-label, multicenter trial designed to evaluate the safety, pharmacokinetics and efficacy of the companies' long-acting, recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B ...
Biogen Idec
dosing
fusion proteins
+3